Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 111 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Comparator: First Intervention (3 weeks) Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

NCT00455325
View directory record Official record
Conditions
Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions
Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation

NCT01772641
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Scheduled Gradual Reduction + Varenicline, Scheduled Gradual Reduction + Placebo Drug, Basic Advice + Varenicline, Basic Advice + Placebo Drug
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence

NCT00713583
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa, Placebo, Cognitive Behavioral Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 2, 2026, 2:27 AM EDT
Suspended Phase 2 Interventional

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT06538389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 2, 2026, 2:27 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Interactive Physical and Cognitive Exercise System

NCT03069391
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, MCI, Aging, Mild Cognitive Impairment, Neurocognitive Disorder, Cognitive Impairment, Cognitive Change
Interventions
physical exercise alone (PES) first, cognitive exercise alone (iCE) first, interactive Physical and Cognitive Exercise (iPACES™)
Behavioral · Device
Lead sponsor
Union College, New York
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

NCT02371889
View directory record Official record
Conditions
Alcoholism, Alcohol Use Disorder (AUD)
Interventions
Topiramate, Medical Management, Inactive Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

The Role Of Omega-3 Fatty Acids In Adolescent Depression

NCT00962598
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Omega 3 Fatty Acids, Corn oil
Drug · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Open Label Placebo in Children With FGIDs

NCT02389998
View directory record Official record
Conditions
Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions
Placebo Suspension, Hyoscyamine
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Not applicable Interventional

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

NCT04478630
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

NCT02824055
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO5545965
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Gold Factor on Knee Joint Health and Function

NCT05347602
View directory record Official record
Conditions
Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
Interventions
Gold Factor (Gold Nanoparticles, AuNPs), Placebo
Dietary Supplement
Lead sponsor
4Life Research, LLC
Industry
Eligibility
18 Years to 87 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Will Hydroxychloroquine Impede or Prevent COVID-19

NCT04341441
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
Interventions
Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
Drug · Other · Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Active, not recruiting Phase 2 Interventional

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters

NCT06009926
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm
Interventions
Acetaminophen, Biospecimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement, Placebo Administration, Questionnaire Administration, Training
Drug · Procedure · Dietary Supplement + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Sympatholysis in Chronic Kidney Disease

NCT02411773
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Placebo, Exercise Training, Control to Exercise (Stretching)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Treatment for Calcium Phosphate Kidney Stone Disease

NCT01754779
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
Placebo, Citric Acid, Potassium Citrate
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tetrahydrocannabinol (THC) and Sleep

NCT03560934
View directory record Official record
Conditions
Sleep, THC, Marijuana, Cannabis
Interventions
Dronabinol
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 34 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

NCT01480232
View directory record Official record
Conditions
Nicotine Dependence, Smoking Cessation
Interventions
EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment
Drug · Behavioral
Lead sponsor
A. Eden Evins
Other
Eligibility
18 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth

NCT06721884
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Artemisia Annua Leaf, placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Solifenacin Succinate Suspension, Placebo, Urotherapy
Drug · Behavioral
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 2, 2026, 2:27 AM EDT